Article Per Year (5 Year)
p-Index From 2021 - 2026
0.778
P-Index
This Author published in this journals
All Journal Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Indonesian Journal of Cancer Narra J Indonesian Journal of Cancer Pharmaceutical Sciences and Research (PSR) Jurnal Penyakit Dalam Indonesia
Noorwati Sutandyo
Jurusan Farmasi Klinik, Fakultas Farmasi, Universitas Indonesia, Depok, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP) Panigoro, Sonar S.; Paramita, Rafika I.; Wanandi, Septelia I.; Fadilah, Fadilah; Wibisana, I GNG.; Sutandyo, Noorwati
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1364

Abstract

Breast cancer subtypes can be categorized based on their gene expression profiles using immunohistochemistry into Luminal A, Luminal B, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes. However, immunohistochemistry has certain limitations that can lead to misclassification. DNA methylation is an epigenetic modification, and changes in the promoter region can alter gene expression and the quantity of functional protein synthesized, disrupting gene function. The aim of this study was to identify DNA methylation biomarkers for subtype classification in breast cancer using microarray and methylation-specific polymerase chain reaction (MSP) methods. DNA samples were extracted, subjected to bisulfite conversion and then used for both the microarray and MSP methods. This study successfully identified differentially methylated CpGs (DMCs) as biomarker for each subtype classification of breast cancer: Luminal A (hypermethylation of ADAMTSL2 gene; cg14397888), Luminal B (hypomethylation of ADAMTSL2 gene; cg14397888), HER2+ (hypermethylation of PTPRN2 gene; cg25910261), and TNBC (hypomethylation of LCLAT1 gene; cg15652532). The DMC biomarker found for the HER2+ subtype, hypermethylation in the PTPRN2 gene (cg25910261), has the potential to be used by healthcare providers to identify HER2+ patients and provide the HER2-targeted therapy to improve the patient’s survival. In addition, our developed MSP method could produce an effective diagnostic tool for classifying the Luminal A and Luminal B subtypes, with accuracies of 75% and 76%, respectively.
Faktor Yang Mempengaruhi Penurunan Fraksi Ejeksi Ventrikel Kiri Pada Pasien Kanker Yang Mendapatkan Kemoterapi Doksorubisin Di Rumah Sakit Kanker Dharmais Maifitrianti, Maifitrianti; Sutandyo, Noorwati; Andrajati, Retnosari
Media Farmasi: Jurnal Ilmu Farmasi Vol. 12 No. 2: September 2015
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/mf.v12i2.3761

Abstract

Doksorubisin masih sering digunakan dalam pengobatan kanker. Efek samping doksorubisin terhadap jantung perlu mendapatkan perhatian khusus. Penelitian ini bertujuan untuk memperoleh gambaran penurunan fraksi ejeksi ventrikel kiri dan faktor risiko yang mempengaruhinya pada pasien kanker yang mendapatkan kemoterapi doksorubisin di Rumah Sakit Kanker Dharmais (RSKD). Desain penelitian yang digunakan adalah cross sectional. Data diperoleh dari rekam medis pasien. Populasi adalah pasien kanker yang mendapatkan kemoterapi doksorubisin minimal 4 siklus periode Oktober 2011-Oktober 2013. Penilaian fungsi jantung didapatkan dari data Echocardiography jantung yaitu fraksi ejeksi ventrikel kiri sebelum kemoterapi dan setelah siklus terakhir kemoterapi. Penurunan fraksi ejeksi ventrikel kiri ≥10% pada penelitian dinilai sebagai penurunan yang bermakna. Analisis statistik menggunakan software Statistical Products Social Science (SPSS) versi 18. Sebanyak 77 pasien memenuhi kriteria inklusi dan eklusi. Sebanyak 37 pasien (48,05%)  mengalami penurunan fraksi ejeksi ventrikel kiri <10% dan sebanyak  28  pasien  (36,36%) mengalami penurunan fraksi ejeksi ventrikel kiri ≥10%. Hipertensi berpengaruh terhadap penurunan fraksi ejeksi ventrikel kiri ≥10% secara bermakna (p=0,032). Jenis kelamin laki-laki dan radiasi dada kiri menunjukkan adanya kecenderungan berhubungan dengan penurunan fraksi ejeksi ventrikel kiri ≥10% (p=0,095 dan p=0,051). Doksorubisin dapat menyebabkan penurunan fraksi ejeksi ventrikel kiri ≥10% pada lebih dari sepertiga pasien kanker di RSKD dan faktor yang paling mempengaruhinya adalah komorbiditas hipertensi. Kata Kunci: doksorubisin; faktor risiko; penurunan fraksi ejeksi ventrikel kiri 
Factor Associated with Mortality of Hospitalized Cancer Patients with COVID-19 Infection in Indonesia National Cancer Center Kurniawati, Sri Agustini; Sutandyo, Noorwati; Tadjoedin, Hilman; Pradipta, Jaka; Ismuha, Ratu Ralna; Ummah, Citra Dovina Khaira; Suryana, Kresna Dharma; Budi, Erwin
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1077

Abstract

Background: Cancer patients with COVID-19 are at risk of developing severe complications and outcomes due to immunosuppressive and inflammatory states. This study aims to provide insight into risk factors associated with mortality in this population. Methods: A retrospective cohort study was conducted at Dharmais National Cancer Center, Jakarta, Indonesia, from May 2020 to July 2021. Data were collected through electronic medical records using the consecutive sampling technique. The numerical and categorical data were then tested statistically. Results: The results showed 180 cancer patients with COVID-19 were hospitalized at Dharmais National Cancer Center. Among the patients, 114 patients survived, and 66 patients deceased. Across all risk factors analyzed to mortality, patients with Diabetes Mellitus (OR 0.41;0.22-0.77, p-value 0.05) and high level of D-dimer (OR 2.00;1.06-3.79, P-value 0.05) have a higher risk in mortality. The Results showed that survived patients have lower D-dimer levels (2010 ng/L) and deceased patients have higher D-dimer levels (3264 ng/L) with P-value 0.05. Conclusion: High D-dimer levels and diabetes are risk factors significantly associated with mortality in hospitalized cancer patients with COVID-19 Infection.
Co-Authors A. M. Jayusman Adli, Mizanul Anwar Jusuf ARIF R HANAFI, ARIF R Birry Karim Budi, Erwin Cleopas M Rumende, Cleopas M Cleopas Martin Rumende Cosphiadi Irawan Dolly Dolven Kansera E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Eddy Suratman EKA WIDYA KHORINAL, EKA WIDYA Em Yunir, Em Erlina Burhan Fadilah Fadilah, Fadilah Fadlina Chany Saputri Griskalia Christine Harahap, Agnes S. HILMAN TADJOEDIN, HILMAN Joedo Prihartono Kardinah -, Kardinah Lugyanti Sukrisman Luhuna, Muslimah Maifitrianti Maifitrianti, Maifitrianti Mohamad Sadikin Mun'im, Abdul NATA LUGITO, NATA Paramita, Rafika I. Philip Waruna, Philip Pradipta, Jaka Ratu Ralna Ismuha Reni Paramita Retnosari Andrajati Rizki Yaruntradhani Rumende, Samuel K Salman Paris Harahap, Salman Paris Sariasih Arumdati Septelia I. Wanandi Setyawan, Lyana Sitorus, Truely P Sonar S. Panigoro Sri Agustini Kurniawati, Sri Agustini Sri Wardatun Suhendro Suwarto, Suhendro Suryana, Kresna Dharma Susanto, Erwin C Ummah, Citra Dovina Khaira Wibisana, I GNG. Yahdiana Harahap